Price Alert: Shares of F-star (FSTX) Trade 5.73% Higher at Midday May 13
Equities Staff Follow |Today F-star Therapeutics Inc (NASDAQ: FSTX) is trading 5.73% higher.
The latest price, as of 11:55:16 est, was $2.28. F-star has risen $0.125 so far today.
147,915 shares exchanged hands.
As of the previous close, F-star has a YTD change of 56.57%. The company expects its next earnings on 2022-08-11.
For technical charts, analysis, and more on F-star visit the company profile.
About F-star Therapeutics Inc
F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.
To get more information on F-star Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: F-star Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer